Barbara D. Wamil
About
In The Last Decade
Barbara D. Wamil
16 papers receiving 269 citations
Peers
Comparison fields: 5 of 58
- Molecular Biology 107
- Oncology 94
- Cancer Research 91
- Pathology and Forensic Medicine 58
- Genetics 47
Countries citing papers authored by Barbara D. Wamil
This map shows the geographic impact of Barbara D. Wamil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara D. Wamil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara D. Wamil more than expected).
Fields of papers citing papers by Barbara D. Wamil
This network shows the impact of papers produced by Barbara D. Wamil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara D. Wamil. The network helps show where Barbara D. Wamil may publish in the future.
Co-authorship network of co-authors of Barbara D. Wamil
This figure shows the co-authorship network connecting the top 25 collaborators of Barbara D. Wamil. A scholar is included among the top collaborators of Barbara D. Wamil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara D. Wamil. Barbara D. Wamil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 68 | |
| 3 | 4 | |
| 4 | 5 | |
| 5 | 10 | |
| 6 | 17 | |
| 7 | Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis. | 10 |
| 8 | 11 | |
| 9 | CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis. | 13 |
| 10 | 11 | |
| 11 | 50 | |
| 12 | Phase I study of the antineovascularization drug CM101. | 35 |
| 13 | 5 | |
| 14 | 21 | |
| 15 | 11 | |
| 16 | 5 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.